University of Pennsylvania

Novartis Ag

Advaxis, Inc.

Harvard College

Dana-farber-cancer Institute Inc.

University of Georgia Research Foundation, Inc.

Reshma Singh

Qilong Wu

Hilmar Erhard Ebersbach

Celeste Richardson

Jennifer Brogdon

Yvonne Paterson

Michael C Milone

David Jonathan Glass

Joan Mannick

Leon Murphy

Jiquan Zhang

Julia Jascur

Carl H June

Thomas Huber

Yongqiang Wang

Marco Ruella

Anu Wallecha

Huijuan Song

Heather Huet

Gabriela Plesa

Eugene Choi

Gordon James Freeman

Gerhard Johann Frey

Hwai Wen Chang

Arlene Helen Sharpe

John Rothman

Jennifer Marie Mataraza

Boris Engels

Donald A Harn, Jr

Saar Gill

Duane Sewell

Lai Wei

Qiumei Yang

Saad Kenderian

Nicholas Souders

Zhen-kun Pan

The invention provides compositions and methods for treating diseases associated with expression of CD33. The invention also relates to chimeric antigen receptor (CAR) specific to CD33, vectors encoding the same, and recombinant T cells comprising the CD33 CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a CD33 binding domain.

Treatment of cancer using a CD33 chimeric antigen receptor

The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.

Treatment of cancer using humanized anti-BCMA chimeric antigen receptor

Provided are compositions and methods for treating diseases associated with expression of mesothelin comprising administering a cell that expresses a chimeric antigen receptor (CAR) specific to mesothelin in combination with a PD-L1 inhibitor.

Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapy

Provided are compositions for use in methods for treating diseases associated with expression of mesothelin comprising administering a cell that expresses a chimeric antigen receptor (CAR) specific to mesothelin in combination with a PD-L1 inhibitor.

Anti-BCMA chimeric antigen receptor

The invention provides compositions and methods for treating diseases associated with expression of CLL-1. The invention also relates to chimeric antigen receptor (CAR) specific to CLL-1, vectors encoding the same, and recombinant cells comprising the CLL-1 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CLL-1 binding domain.

Treatment of cancer using a CLL-1 chimeric antigen receptor

Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor

This invention provides methods and compositions for usingas an adjuvant for enhancing immune responses in a subject.

Listeria-based adjuvants

This invention provides methods and compositions for using a live attenuatedfor inhibiting cell-mediated suppression of anti-disease infiltrating T lymphocytes in a subject having the disease.

[object Object]

This invention provides methods of treating and vaccinating against an antigen-expressing tumor and inducing an immune response against a sub-dominant epitope of antigen, comprising a fusion of an LLO fragment to the antigen or a recombinantstrain expressing the antigen. The present invention also provides recombinant peptides comprising a listeriolysin (LLO) protein fragment fused to a Her-2 protein or fragment thereof, recombinantstrains expressing a Her-2 protein, vaccines and immunogenic compositions comprising same, and methods of inducing an anti-Her-2 immune response and treating and vaccinating against a Her-2-expressing tumor, comprising same.

The present invention includes compositions, methods and kits for inducing an immune response to a tumor and for treating cancer with avaccine strain expressing an antigen fused to a truncated LLO protein.

Methods and compositions for immunotherapy of cancer

The present invention provides recombinant polypeptides comprising an N-terminal fragment of an ActA protein or LLO protein fused to an antigen or a fragment thereof, nucleotides encoding same, recombinant vectors comprising same, and immunogenic and therapeutic methods utilizing same.

Compositions and methods for enhancing the immunogenicity of antigens

Growing community of inventors

Cambridge, MA, United States of America

Reshma Singh